JAK2 V617F mutation and the clinical features in myeloproliferative disorders (CROSBI ID 528894)
Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija
Podaci o odgovornosti
Radić Antolic, Margareta ; Boban, Ana ; Zadro, Renata ; Juričević, Mirjana ; Sučić, Mirna ; Bašić-Kinda, Sandra ; Labar, Boris
engleski
JAK2 V617F mutation and the clinical features in myeloproliferative disorders
Myeloproliferative disorders share clinical and biological similarities that may be influenced by presence of recently discovered point mutation in JAK2 gene (JAK2 V617F). The aim of this study was to determine the correlation between JAK2 V617F mutation and the clinical features of patients with polycythemia vera (PV) and essential thrombocythemia (ET). The study included 36 patients with PV (PV group) and 38 patients with ET (ET group). The diagnosis was established according to the Polycythemia Vera Study Group criteria. The detection of JAK2 V617F was performed by allele specific PCR (Baxter et al., Lancet 2005) on DNA isolated from bone marrow cells or peripheral blood cells. JAK2 V617F positive and negative members of PV and ET groups were analyzed for peripheral blood counts and bone marrow aspiration. JAK2 V617F positive PV patients exhibited statistically significantly higher number of red blood cells, white blood cells and platelets when compared to PV patients negative for JAK2 V617F. No statistically significant difference was found in hemoglobin concentration and hematocrit value. In contrast, JAK2 V617F positive subjects of the ET group had statistically significantly increased number of red blood cells, hemoglobin concentration and hematocrit value, and no significant difference in platelet or white blood cell count. Bone marrow evaluation revealed that JAK2 V617F positive patients of the PV group had myeloid hyperplasia with the excess of eosinophils and platelet clumps, which is consistent with the findings of the peripheral blood analysis. On the contrary, bone marrow evaluation of the ET group did not reveal any significant differences between JAK2 V617F positive and negative patients. Overall our data suggest that JAK2 V617F mutation status could serve as a criterion to categorize both PV and ET patients into distinct subgroups. Further studies are needed to determine whether JAK2 V617F mutation status in myeloproliferative disorders should be used as a criterion for therapy approach.
JAK2 V617F; myeloproliferative disorders
doi: 10.1016/S0145-2126(07)70383-1
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
S80-S80.
2007.
nije evidentirano
objavljeno
Podaci o matičnoj publikaciji
Leukemia research
Bennet, J.M. ; Hamblin, T.J.
Elsevier
0145-2126
Podaci o skupu
Leukemia and Lymphoma 2007 : West and East Together
poster
15.09.2007-19.09.2007
Dubrovnik, Hrvatska
Povezanost rada
Temeljne medicinske znanosti